XenoPort, Inc. (NQ: XNPT)
4.120 USD  -0.060 (-1.44%)
Official Closing Price  /  Updated: 8:10 PM EDT, Apr 15, 2014  /  Add to My Watchlist      
(XNPT) Community Analysis from
April 15, 2014
(Stock Blog Hub, 8/7/13)
XenoPort, Inc. (XNPT) recently reported disappointing results on arbaclofen placarbil (AP) from a pivotal late-stage study (n=228). Results from the phase III trial showed that AP failed...(read more)
(Stock Blog Hub, 8/4/13)
XenoPort Inc. (XNPT) recently commenced shipments of Horizant extended-release tablets in the US. The drug is approved in the US for the treatment of moderate-to-severe primary restless...(read more)
(Stock Wizard, 4/7/11)
Below we highlight few companies whose shares are actively trading in Thursday's session. XenoPort, Inc. (NASDAQ: XNPT) soared more than 60% on Thursday, a day after the drugmaker...(read more)
XenoPort (XNPT) Company Overview

XenoPort is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates for the potential treatment of central nervous system (CNS) disorders and gastroesophageal reflux disease (GERD). The company's drug discovery efforts focus on utilizing the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs. The most advanced product candidate is being developed for the potential treatment of restless legs syndrome (RLS) and the management of neuropathic pain. The company's goal is to develop orally available, patentable new chemical entity that addresses large potential markets using currently marketed drugs that have deficiencies in the oral absorption, distribution and/or metabolism. XenoPort's new candidate, called a Transported Prodrug, is created by modifying the chemical structure of the currently marketed parent drug. XenoPort scientists have designed these Transported Prodrugs to be actively transported from the gastrointestinal, or GI, tract into the bloodstream, where they are metabolized to release the parent drug.

A key component of the company's strategy is to reduce the risks and time associated with drug development by capitalizing on the known safety, efficacy, and established drug development history of the parent drugs. In addition, XenoPort's improved prodrug products are designed to be metabolized to release the parent drugs and natural substances with favorable safety characteristics. This strategy aims to increase the probability of successfully development, as well as potentially expanding the indication for which the parent drugs have not been approved, but are nevertheless used off-label after having demonstrated efficacy in clinical trials. The company is located in Santa Clara, CA and employs approximately 150 professionals.

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here